Anvatabart opadotin by Ambrx Biopharma for Gastric Cancer: Likelihood of Approval

The on­ly clin­i­cal-stage an­ti­body-drug con­ju­gate in Sanofi’s pipeline has flunked a Phase III study, push­ing the French drug­mak­er to wind down the en­tire de­vel­op­ment pro­gram.

Re­vance Ther­a­peu­tics, the mak­er of Botox com­peti­tor Daxxi­fy, will be ac­quired for more than $900 mil­lion. Crown Lab­o­ra­to­ries will buy out … Sign up to